NCLEX-RN · Pharmacological and Parenteral Therapies · 8 min read
Pain Management and Opioid Safety
- Differentiate the mechanisms, dosing limits, and safety profiles of non-opioid analgesics including acetaminophen and nonsteroidal anti-inflammatory drugs.
- Apply safe administration practices for pure opioid agonists by analyzing potency differences, metabolic variations, and organ-specific adverse effects.
- Formulate nursing interventions for respiratory depression, sedation assessment, opioid reversal with naloxone, and patient-controlled analgesia management.
Non-Opioid Analgesic Principles and Safety Limits
Non-opioid analgesics serve as foundational therapies in multimodal pain control. Acetaminophen acts as an effective analgesic and antipyretic agent, meaning it relieves pain and reduces fever. However, acetaminophen completely lacks anti-inflammatory properties. Because acetaminophen is incorporated into many over-the-counter and prescription formulations, monitoring total intake is critical. The maximum recommended daily dose of acetaminophen for healthy adults is generally 3,000 to 4,000 milligrams. Exceeding this threshold places the patient at risk for acute hepatotoxicity. If an overdose occurs, liver injury can develop rapidly, and the specific antidote required to counteract this toxicity is N-acetylcysteine.
NSAIDs inhibit cyclooxygenase and reduce prostaglandin synthesis throughout the body; acetaminophen acts primarily in the central nervous system through mechanisms that may also involve prostaglandins, but has little clinically significant anti-inflammatory effect. These agents inhibit cyclooxygenase enzymes, which in turn reduces prostaglandin synthesis throughout the body. While this action successfully treats pain and inflammation, the reduction of prostaglandins introduces significant clinical risks. Nonsteroidal anti-inflammatory drugs carry significant risks of gastrointestinal ulceration, systemic bleeding, and renal impairment. Nurses must remain vigilant when evaluating patients receiving these drugs, particularly those with pre-existing kidney vulnerability or a history of gastric irritation.
A critical property shared by non-opioid analgesics is the presence of an analgesic ceiling. An analgesic ceiling means that a drug reaches a maximum level of pain relief at a specific dose. Taking doses above that ceiling does not meaningfully improve pain relief, but it does substantially increase the frequency and severity of adverse effects. Consider this like a sponge that has absorbed all the water it can hold; pouring more water over it does not make it any wetter, but it creates a dangerous overflow.
Ketorolac represents a potent nonsteroidal anti-inflammatory drug that demands strict adherence to administration limits. Ketorolac is available in parenteral and oral forms, but oral ketorolac is used only as continuation of initial intravenous or intramuscular therapy. However, total treatment with ketorolac must not exceed five days because of severe risks that include gastrointestinal bleeding and renal toxicity. When managing patients prescribed ketorolac, nurses must track the cumulative duration of therapy across all routes combined to protect kidney function and prevent severe gastrointestinal complications.
| Medication Class / Drug | Mechanism & Properties | Clinical Limits & Duration | Adverse Risks & Specific Antidote |
|---|---|---|---|
| Acetaminophen | Analgesic and antipyretic; lacks anti-inflammatory properties | Maximum 3,000 to 4,000 mg daily for healthy adults; exhibits an analgesic ceiling | Acute hepatotoxicity; specific antidote is N-acetylcysteine |
| General NSAIDs | Inhibit cyclooxygenase enzymes and reduce prostaglandin synthesis | Exhibits an analgesic ceiling; higher doses increase harm without added relief | Gastrointestinal ulceration, bleeding, and renal impairment |
| Ketorolac | Potent NSAID available in parenteral and oral formulations | Total treatment must not exceed five days across all routes combined | Severe gastrointestinal bleeding and renal toxicity |
Common mistakes
- Assuming that morphine and hydromorphone can be administered at the same milligram dose, overlooking that hydromorphone is substantially more potent and requires significantly smaller milligram amounts.
- Relying solely on pulse oximetry to monitor for respiratory depression instead of recognizing that capnography detects hypoventilation earlier.
- Allowing well-meaning family members or visitors to press a patient-controlled analgesia button while the patient sleeps, which bypasses built-in safety mechanisms and risks fatal overdose.
- Treating opioid-induced constipation with extra dietary fiber alone or a stool softener alone, ignoring that opioids impair propulsive motility and generally require a stimulant laxative.
Key points
- Acetaminophen provides analgesia and antipyresis without anti-inflammatory action; daily intake must not exceed 3,000 to 4,000 mg in healthy adults to avoid hepatotoxicity, which is treated with N-acetylcysteine.
- Nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase enzymes, reduce prostaglandins, carry GI and renal risks, and include ketorolac, which must never exceed five days of total therapy.
- Pure opioid agonists lack an analgesic ceiling, hydromorphone is far more potent than morphine, and fentanyl is dosed in micrograms; transdermal fentanyl is strictly for chronic pain in opioid-tolerant patients and must never contact external heat.
- Codeine requires hepatic CYP2D6 metabolism to morphine, placing CYP2D6 ultra-rapid metabolizers at risk for severe opioid toxicity and respiratory arrest from standard doses.
- Respiratory rates below 10 breaths per minute require prompt assessment, rates below 8 warrant immediate intervention, and a Pasero score of 3 requires holding the opioid and notifying the prescriber, while a score of 4 requires stopping the opioid and urgent intervention.
- Naloxone reverses respiratory depression but lasts only 30 to 90 minutes, risking rebound depression; it should be titrated slowly in dilute doses postoperatively to prevent acute withdrawal, pain, tachycardia, and pulmonary edema.
- On patient-controlled analgesia, only the patient may press the button; if the patient becomes unarousable or exhibits profound bradypnea, the nurse's first action is to stop the pump before supporting ventilation and administering naloxone.
Practice this section
Explained NCLEX Pharmacological and Parenteral Therapies questions, no account needed. NCLEX Pharmacological and Parenteral Therapies practice test
The full lesson continues with 3 more sections with exam tips, audio in English and Spanish, 5 Check yourself questions and 20 flashcards.
- 1 month
$58.99$29.49 - 3 months
$173.99$86.99 - Lifetime
$350.99$175.49
One payment, no subscription.
See NCLEX plansAlready a member? Log in
Sample lesson: Medication Safety and the Rights of Administration25 practice questions on this exam
Each NCLEX practice test has 25 original questions with the answers explained. No account needed.
Open the NCLEX practice testsOriginal lesson written for NCLEX-RN practice · updated October 31, 2026. Exam names are trademarks of their owners; tests.global is not affiliated with them.